Design and Synthesis of Potent, Selective Inhibitors of Matriptase

Eloïc Colombo, Antoine Désilets, Dominic Duchêne, Félix Chagnon, Rafael Najmanovich, Richard Leduc, and Eric Marsault

ACS Med. Chem. Lett., Just Accepted Manuscript • DOI: 10.1021/ml3000534 • Publication Date (Web): 11 Apr 2012

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
Design and Synthesis of Potent, Selective Inhibitors of Matriptase.

Éloïc Colombo, 1 Antoine Désilets, 1 Dominic Duchêne, 2 Félix Chagnon, 1 Rafael Najmanovich, 2 Richard Leduc, 1 and Eric Marsault 1*

Department of Pharmacology, Department of Biochemistry, Faculty of Medicine and Health Sciences, Université de Sherbrooke, 3001 12e av Nord, Sherbrooke PQ, Canada J1H5N4.

KEYWORDS: Matriptase, Type II transmembrane serine protease, slow tight-binding inhibitor.

ABSTRACT: Matriptase is a member of the type II transmembrane serine protease family. Several studies have reported deregulated matriptase expression in several types of epithelial cancers, suggesting that matriptase constitutes a potential target for cancer therapy. We report herein a new series of slow, tight-binding inhibitors of matriptase, which mimic the P1-P4 substrate recognition sequence of the enzyme. Preliminary Structure-Activity Relationships indicate that this benzothiazole-containing RQAR-peptidomimetic is a very potent inhibitor and possesses a good selectivity for matriptase versus other serine proteases. A molecular model was generated to elucidate the key contacts between inhibitor 1 and matriptase.

Cell surface proteolysis is an important mechanism for the degradation or generation of biological effectors that engage various signalling pathways. Recently, a novel family of proteolytic enzymes called type II transmembrane serine proteases (TTSPs), has been associated with crucial roles in numerous physiological processes.

In humans, the 17 members of this family are divided into four subfamilies: HAT/DESC, Hepsin/TMPRSS, Corin and matriptase. These transmembrane proteases are structurally defined by a cytoplasmic amino-terminal region, a transmembrane domain, a stem region that contains various functional domains and a carboxy-terminal extracellular serine protease domain of the chymotrypsin (S1) fold, characterized by the canonical histidine, aspartate and serine catalytic triad essential for proteolytic activity. Matriptase, one of the most characterized TTSPs to date, is expressed in epithelial cells where it carries out essential functions in development, differentiation and maintenance of epithelial barrier homeostasis. Matriptase knockout mice die shortly after birth due to severe dehydration caused by impaired epidermal barrier function, indicative of a crucial role in development. Amongst the most recognized matriptase substrates are pro-hepatocyte growth factor, pro-prostaglandin, protease activated receptor-2 (PAR-2), pro-urokinase plasminogen activator, CUB domain containing protein-1 and platelet-derived growth factor-D.

Like many other proteases, the inactive zymogen precursor of matriptase needs to be converted to its active form. This is achieved via an initial cleavage occurring at residue Gly 149, followed by an auto-proteolytic cleavage at residue Arg 612 within the RQAR 614-VVGG sequence of the activation peptide of matriptase. Matriptase forms complexes with its cognate Kunitz-type serine protease inhibitor, the hepatocyte growth factor activator inhibitor-1 (HAI-1), which is involved in activation, inhibition, expression and trafficking of the enzyme. Several studies have shown that the proteolytic activity of matriptase must be tightly regulated during development, and deregulated matriptase activity has been linked to various pathologies. For example, a rare genetic skin disorder, autosomal recessive ichthyosis with hypotrichosis (ARIJH), was found to be caused by mutations in the matriptase coding region, leading to the production of an inactive protease. Elevated levels of matriptase in osteoarthritis are thought to facilitate the induction of cartilage destruction, while lowered levels have been detected in colonic epithelia of inflammatory bowel disease patients. Matriptase is overexpressed in a variety of epithelial cancers and causes malignant transformations when orthotopically overexpressed in the skin of mice, suggesting a causal role in human carcinogenesis. The latter findings suggest that deregulation of matriptase expression or activity is involved in the initiation and/or progression of cancer. Combined with its localization at the cellular surface of epithelial cells, matriptase appears as an attractive therapeutic target for the design and optimization of selective inhibitors to better understand its role in pathologies such as cancer. Several groups have been interested in the development of such inhibitors via different strategies.

In this study, we report a new class of potent and selective peptidomimetic inhibitors of matriptase based on the P4-P1 (Arg-Gln-Ala-Arg) portion of the activation peptide of matriptase, to which was linked a carboxy-terminal serine trap in the form of a ketobenzothiazole group. The ketobenzothiazole serine trap was selected to form a covalent bond with the catalytic serine residue of the enzyme as reported by Costanzo et al. on thrombin. The use of a serine trap is reminiscent of the recently approved HCV NS3-4A protease inhibitors Boceprevir and Telaprevir. Herein, we report the synthesis, inhibitory activity, preliminary structure-activity relationships and selectivity of this new class of inhibitors, and propose a molecular model of inhibitor 1 docked into the active site of matriptase.

RESULTS AND DISCUSSION

Synthetic strategy. The inhibitor sequence is based on the natural auto activation peptide sequence of matriptase Arg-Gln-Ala-Arg (RQAR) explored by our group, to which was added a ketobenzothiazole serine trap (Figure 1).
Figure 1. Chemical structure of inhibitor 1.

Synthetically, inhibitor 1 and its analogues were assembled similarly to the method reported by Costanzo et al.\(^1\) by peptide coupling of warhead-functionalized P1 fragment 8 with protected P4-P2 fragment 10 (Schemes 1 and 2). The synthesis of inhibitor 1 is shown as an example. Firstly, fragment 8 carrying the serine trap was prepared from the corresponding Weinreb amide 7, by addition of in situ generated 2-lithio-benzothiazole.\(^1\) The resulting ketobenzothiazole was reduced in the same operation with NaBH\(_4\) as a means of protecting the electrophilic keto group, then the Boc group was deprotected by acidolysis. On the other hand, L-Ala benzyl ester tosylate was coupled with Fmoc-Gln-OH using HATU to afford dipeptide 9. After Fmoc removal, the crude dipeptide was coupled with Boc-Arg(Mtr)-OH in the presence of EDC and HOBT to give the corresponding fully protected tripeptide. Benzyl ester hydrogenolysis then generated the desired fragment 10. Subsequent coupling of tripeptide 10 with warhead 8 provided intermediate 11 (Scheme 2). The tetrapeptide scaffold 11 was then oxidized with IBX\(^2\), followed by final acidolysis of protective groups with HF. Compounds were generally obtained as a 8:2 mixtures of epimers,\(^1\) which were separated by reverse-phase preparative HPLC. Structural analogs 2-7 (Table 1) were obtained according to the same synthetic method.

**Scheme 1. Synthesis of tripeptide 11.**

Scheme 2. Assembly of fragments.

Reagents and conditions: (a) HN(Me)OMe, HATU, DIPEA, THF r.t.; (b) Benzothiazole, n-Buli, THF -78°C; (c) NaBH\(_4\), MeOH, -20°C; (d) TFA/DCM 20:80, r.t.; (e) Fmoc-Gln(Trt)-OH, HATU, DIPEA, THF, r.t.; (f) EtNH/DCM 20:80, r.t; (g) Boc-Arg(Mtr)-OH, EDC-HOBt, DCM, r.t; (h) H\(_2\), Pd/C (10%) EtOH, r.t.

**Enzyme inhibition assays.** Firstly, the inhibitory activity of tetrapeptide 1 toward matriptase was characterized. The progress curve for hydrolysis of a fluorogenic substrate by matriptase (1nM) in the presence of compound 1 (2.5 nM) displays a biphasic curve with a rapid initial phase and a slower, steady-state phase (data not shown), suggesting reversible slow, tight-binding or irreversible inhibition.

To further evaluate the inhibitor profile, the dissociation of the enzyme: inhibitor complex (EI) was investigated using dilution experiments.\(^2\) Figure 2 reports the comparison of the dissociation curves for compound 1 (Fig. 2A) and irreversible inhibitor Glu-Gly-Arg chloromethyl ketone (EGR-CMK) (Fig. 2B). The dissociation curve of EGR-CMK displays a linear product versus time relationship, indicative of irreversible inhibition. Conversely, the dissociation curve of inhibitor 1 shows an exponential shape, suggesting dissociation of the enzyme: inhibitor complex. Together, these data confirm the formation of a slow, tight-binding and reversible complex between inhibitor and enzyme, as initially designed.

**Figure 2. Dissociation of enzyme: inhibitor (EI) complex.**

Matrionase and increasing concentrations of (A) RQR-Benzo or (B) EGR-CMK were pre-incubated for 20 minutes at room temperature and diluted 2000 times in reaction buffer containing 400 µM Boc-QAR-AMC. Final concentration of matrionase is 0.25 nM and is varied as indicated for inhibitors. Proteolytic activity in the reaction buffer was measured as de-
scribed in materials and methods (see Supplementary Information).

To further characterize matriptase inhibition by compound 1, the inhibition constant ($K_i$) was determined using the Morrison equation for reversible tight-binding inhibition. In these conditions, the RQAR-ketobenzothiazole inhibitor 1 showed high potency for matriptase, with a $K_i$ of 0.011 nM (Table 1).

A preliminary analysis of Structure-Activity Relationships (SAR) was subsequently performed by exploring the critical P1 position. In order to confirm the importance of the keto group for matriptase inhibition, we measured the inhibitory activity of a reduced form of the RQAR-ketobenzothiazole toward matriptase (compound 2, Table 1). Reduced analog 2 (3:2 mixture of diastereomers at the alcohol position, undetermined absolute stereochemistry) displayed very weak inhibition, as expected. Indeed, a stoichiometric ratio of I/E > 1000 was required in order to observe substantial inhibition, as testified by a $K_i$ of 6.1 µM, which contrasts with the much more potent oxidized form 1 and is consistent with a functional serine trap mechanism.

### Table 1. Preliminary Structure-Activity Relationships.

<table>
<thead>
<tr>
<th>Inhibitor</th>
<th>$K_i$ (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>R Q A R</td>
<td>0.011 $^{\text{b}}$ ± 0.0004</td>
</tr>
<tr>
<td>H, OH$^a$</td>
<td>6124 $^{\text{mnm}}$ ± 2702</td>
</tr>
<tr>
<td>R Q A K</td>
<td>9.5 $^{\text{b}}$ ± 1.3</td>
</tr>
<tr>
<td>O</td>
<td>0.088 $^{\text{b}}$ ± 0.010</td>
</tr>
<tr>
<td>O</td>
<td>1.4 $^{\text{b}}$ ± 0.3</td>
</tr>
<tr>
<td>R</td>
<td>457 $^{\text{mm}}$ ± 132</td>
</tr>
<tr>
<td>R Q A -(D)R</td>
<td>4.6 $^{\text{b}}$ ± 0.8</td>
</tr>
</tbody>
</table>

$K_i$ values were determined as described in materials and methods (tb: tight-binding, mm: mixed model). Measurements of enzymatic activity were performed in triplicate and represent the mean ± standard deviation of at least three independent experiments. (a) 3:2 mixture of diastereomers, absolute stereochemistry undetermined.

Table 1 reports the influence of structural variations of peptidomimetic 1 on matriptase inhibition. In order to ascertain the importance of stereochemistry at the P1 position, analogue R-Q-A-(D)R 7 was tested and displayed a 400-fold lower inhibition.

Next, it is known that the type II transmembrane serine proteases have a preference for basic residues (Lys or Arg) in position P1. Accordingly, matriptase displays a preference for an Arg residue in position P1 by almost 3 orders of magnitude over Lys (3 vs 1, $K_i$ 0.011 nM vs 9.5 nM). Furthermore, in order to better ascertain the respective contribution of the P4, P3 and P2 residues on inhibitory profile, the peptidic portion was truncated by one, two and three residues starting from the N-terminal extremity (analougues 4-6). Deletion of the P4 residue gave a compound that conserves the profile of a tight binding inhibitor, yet with an 8-fold decreased potency compared to 1 (4, $K_i$ 0.088 nM vs 0.011 nM). Inhibitor 5, in which the P4 and P3 moieties were simultaneously deleted, remains a tight binding inhibitor with 127-fold reduced potency compared to 1 ($K_i$ 1.4 nM vs 0.011 nM). Finally, inhibitor 6, in which the P4-P2 tripeptide portion is removed, is dramatically less potent, with a $K_i$ of 457 nM, over 30 000-fold less potent than inhibitor 1. Additionally, 6 no longer behaves as a tight-binding inhibitor but as an inhibitor possessing a mixed mode of inhibition as determined by global fitting analysis for different modes of inhibition (see Supplementary Information). Altogether, these results confirm the importance of residues at the P4-P2 positions for potent inhibition of matriptase.

The selectivity profile of inhibitor 1 for matriptase vs other serine proteases, including TTSPs, was subsequently determined (Table 2). Indeed, the selectivity of most published matriptase inhibitors has not been reported vs other TTSPs. Experimental $K_i$ were determined as described in Materials and Methods (see Supplementary Information) for inhibitor 1 against other TTSPs (hepsin, matriptase-2, TMPRSS11D) and serine proteases (trypsin, thrombin). Selectivity was expressed as the ratio of $K_i$s. Compound 1 was found to be highly selective for matriptase vs other enzymes: trypsin (88-fold), hepsin (100-fold), matriptase-2 (300-fold), TMPRSS11D (764-fold), thrombin (>30000-fold) and furin (no inhibition). This high level of selectivity of the RQAR-Benzothiazole sequence for matriptase relative to other trypsin-like proteases is remarkable. Although at this stage the structural reasons for such selectivity are not elucidated, additional studies, including molecular modeling and crystallography are underway to provide an explanation for this level of selectivity.

### Table 2. Selectivity profile

<table>
<thead>
<tr>
<th>Proteases</th>
<th>$K_i$ (nM)</th>
<th>Selectivity ($K_i$ other/$K_i$ matriptase)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matriptase</td>
<td>0.011 $^{\text{b}}$ ± 0.0004</td>
<td></td>
</tr>
<tr>
<td>Matriptase-2</td>
<td>3.3 $^{\text{b}}$ ± 1.0</td>
<td>300</td>
</tr>
<tr>
<td>Hepsin</td>
<td>1.1 $^{\text{b}}$ ± 0.3</td>
<td>100</td>
</tr>
<tr>
<td>TMPRSS11D</td>
<td>8.4 $^{\text{b}}$ ± 2.6</td>
<td>764</td>
</tr>
<tr>
<td>Trypsin</td>
<td>0.97 $^{\text{b}}$ ± 0.17</td>
<td>88</td>
</tr>
<tr>
<td>Thrombin</td>
<td>637 $^{\text{mm}}$ ± 131</td>
<td>&gt;300000</td>
</tr>
<tr>
<td>Furin</td>
<td>NI (10 µM)</td>
<td></td>
</tr>
</tbody>
</table>

$K_i$ values were determined as described in material and methods (tb: tight binding, mm: mixed model, NI: no inhibition). Enzymatic measurements were performed in triplicate and represent the mean ± standard deviation of at least three independent experiments.

Molecular modeling: In order to understand the preferred mode of docking of inhibitor 1 in the active site of matriptase and rationalize Structure-Activity Relationships, a molecular model of inhibitor 1 docked in the published X-ray structure of matriptase was built (Figure 3). According to this docking
model, the side chain of residue Arg in P1 is highly stabilized in a network of hydrogen bonds, which includes a salt bridge with matriptase residue Asp<sup>799</sup>, a hydrogen bond with Ser<sup>800</sup> and hydrogen bonds with the backbone amide of Gly<sup>827</sup> and Gly<sup>828</sup>. This may account for the preference of Arg over Lys in P1, particularly since the S1 pocket seems to be best suited to accommodate the side chain of Arg instead of Lys, which is longer and possesses reduced hydrogen bond capability compared to Arg. Residue Ala in P2 of inhibitor 1 lays over Phe<sup>708</sup>, which separates the S2 and the S4 pockets. This pocket is quite non-polar due to the presence of the Phe<sup>708</sup> residue. It can also accommodate larger residues, in agreement with our previous results on substrate preference, which demonstrated that the S2 pocket could accommodate residues as large as Arg or Tyr. The side chain of residue Gln in P3 of inhibitor 1 bridges over the Arg residue in P1 to interact with Gln<sup>802</sup> in the S3 pocket. Next, the side chain of the Arg residue in P4 of inhibitor 1 interacts with the side chain of Asp<sup>829</sup> of matriptase via a salt bridge. It also interacts via hydrogen bonding with Gln<sup>833</sup>. Finally, the catalytic Ser<sup>835</sup> residue is adequately positioned in the vicinity of the carbonyl moiety of the ketobenzothiazole group to form a covalent, reversible bond in the form of a hemiacetal. The oxygen atom of the carbonyl group is stabilized via hydrogen bonding with the backbone amides of residues Gly<sup>800</sup> and Ser<sup>805</sup>.

**Figure 3: Docking of inhibitor 1 in the active site of matriptase.** Matriptase<sup>19</sup> is shown in grey and residues within the active site. Inhibitor 1 is shown in orange. Catalytic triad residues are shown in red. The image was generated using Pymol<sup>28</sup>. Numbers refer to matriptase numbering.

In conclusion, we herein report a new series of potent, peptidomimetic inhibitors of matriptase. We have demonstrated that a tetrapeptide scaffold based on the natural auto activation sequence of matriptase is suitable for the design of potent slow, tight binding inhibitors with sub-nM potency. Moreover, inhibitor 1 possesses a high level of selectivity for matriptase vs other serine proteases, including TTSPs. Efforts are underway to further improve the profile of this inhibitor, to account for the observed level of selectivity and use it to validate the role of matriptase in several diseases.

**Supporting Information.** Synthetic procedures, characterization data, biological methods and molecular modeling procedures. This material is available free of charge via the Internet at http://pubs.acs.org.

**AUTHOR INFORMATION**

**Corresponding Author**
Prof E. Marsault, Department de Pharmacologie
Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, 3001 12e Avenue Nord, Sherbrooke, QC, J1H5N4 (Canada)
E-mail : Eric.Marsault@Usherbrooke.ca

**ACKNOWLEDGMENT**

We wish to thank Université de Sherbrooke and the Canadian Institutes of Health Research for financial support (CIHR, MOP-97964). Professors B. Guerin and Y. Dory are acknowledged for sharing purification equipment.

**ABBREVIATIONS**

DPEA: N,N-Diisopropylethylamine
EDC: (1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride)
HOBt: N-Hydroxybenzotriazole
IBX: 2-Iodoxybenzoic acid
TFA: Trifluoroacetic acid
MeOH: Methanol
DMF: Dimethylformamide
DMSO: Dimethylsulfoxide
n-Buli: n-Butyllithium
HPLC: High-Performance-Liquid Chromatography

**REFERENCES**

6. He, Y.; Wortmann, A.; Burke, L. J.; Reid, J. C, Adams, M. N.; Abdul-Jabbar, I.; Quigley, J. P.; Leduc, R.; Kirchhofer, D.; Hooper, J. D. Proteolysis-induced N-terminal ectodomain shedding of the integral membrane glycoprotein CUB domain-containing protein 1 (CDCP1) is accompanied by tyrosine...


37. Sousa Da Silva, A. W.; Vranken, W. F.; Laue, E. D. ACPYPE. AnteChamber PYthon Parser interfacE. *Manuscript to be submitted.*


Design and Synthesis of Potent, Selective Inhibitors of Matriptase.

Éloïc Colombo, 1 Antoine Désilets, 1 Dominic Duchêne, 2 Félix Chagnon, 1 Rafael Najmanovich, 2 Richard Leduc, 1 and Eric Marsault 1 *

For Table of Contents Only